Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Gossamer Bio's latest analyst update leaves the model fair value unchanged at US$4.46 per share and highlights an underweight stance, anchored by a sharply lower US$0.28 price target from some on the Street. That gap reflects concerns around liquidity, going concern warnings, and the impact of recent financing decisions, as well as suspended coverage from at least one major bank that views current visibility as limited. Read on to see how these moving parts fit together and how you can keep track of the evolving narrative around Gossamer Bio.
Stay updated as the Fair Value for Gossamer Bio shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Gossamer Bio.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Barclays highlights that Gossamer Bio's recent exchange offer for its 2027 notes reduces debt and extends the maturity profile. The firm cites this as a positive step for the balance sheet.
-
The same Barclays commentary points out that, despite concerns about dilution, the liability management move gives Gossamer Bio more time to work on execution around its pipeline and funding options.
🐻 Bearish Takeaways
-
Goldman Sachs, through analyst Paul Choi, has suspended its rating, price target, and earnings estimates for Gossamer Bio, citing the going concern warning and uncertainty around securing additional capital to fund operations.
-
Barclays reduced its price target on Gossamer Bio shares to US$0.28 from US$0.30 and reaffirmed an Underweight stance, pointing to the equity dilutive nature of the 2027 note exchange even as it improves the debt profile.
-
Recent commentary from Cantor Fitzgerald has turned more cautious on Gossamer Bio, with downgrades that signal increased skepticism around execution and equity risk at current valuation levels.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Gossamer Bio. See which could impact your investment.
How This Changes the Fair Value For Gossamer Bio
-
Fair value in the model is unchanged at US$4.46 per share.
-
Forecast revenue growth remains at 42.09%.
-
Projected net profit margin is steady at 9.78%, with only rounding differences.
-
The future P/E multiple is effectively flat at 104.90x.
-
The discount rate used in the model is unchanged at 12.46%.
Never Miss an Update: Follow The Narrative
Narratives link Gossamer Bio's clinical and financing story to a detailed financial forecast and fair value, updating as new trials, partnerships, and filings come through. They help you see how individual headlines feed into a bigger, coherent investment case.
Head over to the Simply Wall St Community and follow the Narrative on Gossamer Bio to stay up to date on:
-
Progress of the PROSERA Phase III trial for seralutinib in pulmonary arterial hypertension and what full enrollment means for potential future product approval.
-
The global Phase III collaboration with Chiesi Group in PH-ILD, including expanded dosing strategies that aim to widen the addressable patient base.
-
Key risks around high R&D spend relative to revenue, reliance on successful Phase III outcomes, and the limited cash runway to the first half of 2027.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GOSS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
